Genmab — Maj 2021

[E_L]

On 20 May 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions recommending changes to the terms of the marketing authorisation for the medicinal product Darzalex
https://www.ema.europa.eu/en/medicines/human/summaries-opinion/darzalex-2

[Bulder]

So in a couple of weeks the EU comission will take the final, formal descision.

[Bulder]

Sometimes Genmab sends out messages, when CHMP recommends positive.

[E_L]

Amyloidosis
application was early november, pretty fast

[lahn1]

Tak Bulder

[peter12]

Bulder jeg tror CR er et RECIST kriterie og CMR et PET-CT men ellers ved jeg ikke

[Bulder]

Nederst i denne artikel står at recist-kriterier ikke kan bruges til lymfomer https://pri.rn.dk/Sider/19237.aspx

[E_L]

here is your release @Bulder . I was told they made it specially for you. https://ir.genmab.com/news-releases/news-release-details/genmab-announces-janssen-has-received-positive-chmp-opinion

[Bulder]

In the "old" days you could have these messages in your mail-box. What happenned to that arrangement?

[Helge_LarsenPI-redaktør]

https://www.proinvestor.com/investornyt/675306/genmab-far-stotte-fra-komite-under-ema-til-darzalex-kombi-ny

[E_L]

15:23 for me, but it had to travel further all the way to NL!

[Bulder]

Hvor har I meldt jer til? Jeg fik dem også førhen. Men pludselig holdt det op.

[E_L]

you did ask Jan some very difficult questions in the Q&A Bulder ; was that when the emails stopped ?

[Bulder]

Det lyder sandsynligt Mails er ikke for fattigrøve

[deleted-user]

15:10 - jeg må sidde tæt på serveren

[JørgenVarnæs]

Fattigrøve kan begynde her - https://ir.genmab.com/email-alert-subscription#content

[Bulder]

Tak JV. Jeg har ledt og ledt efter det.

[E_L]

Did we not assume roughly 10% market size for amyloidosis vs MM?

[deleted-user]

Pokkers. Var det ikke sidste år? God pinseferie til jer alle, når I kommer så langt,

[E_L]

the press release reads 'It is estimated that in 2019 there were 4,388 diagnosed incident cases of AL amyloidosis in the five major European markets.2'